» Articles » PMID: 34173891

Comparison of Three Embolic Materials at Partial Splenic Artery Embolization for Hypersplenism: Clinical, Laboratory, and Radiological Outcomes

Abstract

Purpose: To compare effectiveness of three widely used embolic agents in partial splenic embolization (PSE) by analyzing their clinical, laboratory, and radiological outcomes within one year of follow-up.

Materials And Methods: This retrospective study examined 179 patients who underwent PSE to manage hypersplenism secondary to cirrhosis. Patients were divided into 3 groups according to embolic agent used. Group 1 (gelatin sponge) included 65 patients, group 2 (embospheres) included 58 patients, and group 3 (PVA) included 56 patients. Clinical, laboratory, and radiological outcomes were compared between groups.

Results: The technical success rate was 100% in all groups. Pain as a major complication was lower in the gelatin sponge group (20%) compared to the embosphere group (31%) and PVA group (32.3%). Major complications other than pain were found in 20.1%; 24.6% in gelatin sponge group, 15.5% in embosphere group and 19.6% in PVA group (p = 0.045). WBCs and platelet counts showed a significant increase after PSE in all groups. Entire splenic volume as measured by computed tomography after PSE showed no significant difference among the 3 groups; however, the volume of infarcted spleen was significantly lower in the gelatin sponge group compared to other two groups (p = 0.001). The splenic span was significantly reduced one-year post-procedure in three groups (p = 0.006), and it was significantly less in embosphere and PVA groups compared to gelatin sponge group (p < 0.05). Recurrent bleeding was higher in gelatin sponge group (p < 0.05).

Conclusions: Permanent embolic materials achieved better laboratory and radiological outcomes than gelatin sponge particles in PSE of cirrhotic hypersplenism patients. However, permanent particles were associated with greater abdominal pain.

Citing Articles

Effectiveness of partial splenic embolization in colorectal cancer patients with chemotherapy-induced thrombocytopenia: results of a single institution retrospective study.

Li D, Peng T, Wu K, Huang Y, Liu Y, Wan Y Front Oncol. 2024; 14:1468744.

PMID: 39529828 PMC: 11551041. DOI: 10.3389/fonc.2024.1468744.


Organ-preserving embolization of a giant splenic hemangioma in an adult.

Siderakis M, Dodoura S, Gkeneralis G, Kartsouni V, Gkeli M CVIR Endovasc. 2024; 7(1):79.

PMID: 39514074 PMC: 11549259. DOI: 10.1186/s42155-024-00491-1.


Splenic Arterial Embolization for Trauma and Beyond: A Case Series.

Choy C, Lee Y, Cheung P, Ho C, Siu J Vasc Specialist Int. 2024; 40:18.

PMID: 38845443 PMC: 11157332. DOI: 10.5758/vsi.240030.


In Vitro Characterization of Drug-Loaded Superabsorbent Polymer Microspheres: Absorption and Release Capacity of Contrast Material, Antibiotics and Analgesics.

Narita A, Nakano Y, Okada H, Yamamoto T, Matsunaga N, Ikeda S Cardiovasc Intervent Radiol. 2023; 46(11):1632-1640.

PMID: 37759091 DOI: 10.1007/s00270-023-03559-y.


Simultaneous CSM-TACE with CalliSpheres and partial splenic embolization using 8spheres for hepatocellular carcinoma with hypersplenism: Early prospective multicenter clinical outcome.

Zhou J, Feng Z, Liu S, Li X, Liu Y, Gao F Front Oncol. 2022; 12:998500.

PMID: 36530976 PMC: 9751962. DOI: 10.3389/fonc.2022.998500.


References
1.
Smith M, Ray C . Splenic artery embolization as an adjunctive procedure for portal hypertension. Semin Intervent Radiol. 2013; 29(2):135-9. PMC: 3444868. DOI: 10.1055/s-0032-1312575. View

2.
Kimura F, Ito H, Shimizu H, Togawa A, Otsuka M, Yoshidome H . Partial splenic embolization for the treatment of hereditary spherocytosis. AJR Am J Roentgenol. 2003; 181(4):1021-4. DOI: 10.2214/ajr.181.4.1811021. View

3.
Vaidya S, Tozer K, Chen J . An overview of embolic agents. Semin Intervent Radiol. 2011; 25(3):204-15. PMC: 3036437. DOI: 10.1055/s-0028-1085930. View

4.
Sakai T, Shiraki K, Inoue H, Sugimoto K, Ohmori S, Murata K . Complications of partial splenic embolization in cirrhotic patients. Dig Dis Sci. 2002; 47(2):388-91. DOI: 10.1023/a:1013786509418. View

5.
Sangro B, Bilbao I, Herrero I, Corella C, Longo J, Beloqui O . Partial splenic embolization for the treatment of hypersplenism in cirrhosis. Hepatology. 1993; 18(2):309-14. View